Table 2 Correlations between chromosomal instability status and clinicopathologic characteristics.
From: Centromere 17 copy number gain reflects chromosomal instability in breast cancer
Clinicopathologic characteristics | Chromosomal instability | p value | |
|---|---|---|---|
Low | High | ||
Age | Â | Â | 0.266 |
  <50 years | 188 (55.8) | 63 (50.0) |  |
  ≥50 years | 149 (44.2) | 63 (50.0) |  |
T stage | Â | Â | 0.007 |
  T1 | 157 (46.6) | 41 (32.5) |  |
  T2–4 | 180 (53.4) | 85 (67.5) |  |
Lymph node metastasis | Â | Â | 0.010 |
  Absent | 195 (57.9) | 56 (44.4) |  |
  Present | 142 (42.1) | 70 (55.6) |  |
Histologic grade* | Â | Â | <0.001 |
  I & II | 185 (57.3) | 47 (38.2) |  |
  III | 138 (42.7) | 76 (61.8) |  |
Lymphovascular invasion | Â | Â | 0.010 |
  Absent | 203 (60.2) | 59 (46.8) |  |
  Present | 134 (39.8) | 67 (53.2) |  |
Hormone receptor | Â | Â | 0.024 |
  Positive | 245 (72.7) | 78 (61.9) |  |
  Negative | 92 (27.3) | 48 (38.1) |  |
HER2 status | Â | Â | <0.001 |
  Negative | 289 (85.8) | 86 (68.3) |  |
  Positive | 48 (14.2) | 40 (31.7) |  |
p53 overexpression* | Â | Â | 0.001 |
  Absent | 273 (81.0) | 83 (66.4) |  |
  Present | 64 (19.0) | 42 (33.6) |  |
Ki-67 index | Â | Â | <0.001 |
  <20% | 217 (64.4) | 53 (42.1) |  |
  ≥20% | 120 (35.6) | 73 (57.9) |  |
Molecular subtype | Â | Â | <0.001 |
  Luminal/HER2-negative subtype | 224 (66.5) | 59 (46.8) |  |
  Luminal/HER2-postive subtype | 21 (6.2) | 19 (15.1) |  |
  HER2-positive subtype | 27 (8.0) | 21 (16.7) |  |
  Triple-negative subtype | 65 (19.3) | 27 (21.4) |  |
CEP17 copy number gain* | Â | Â | <0.001 |
  Absent | 310 (92.8) | 91 (72.2) |  |
  Present | 24 (7.2) | 35 (27.8) |  |
